IngredientsTheaflavins (TFs) are regarded as the "golden molecules" separated from tea (Camellia sinensis, family Theaceae). Black tea leaves are tea leaves in which green tea catechins are oxidized by endogenous polyphenol oxidase or peroxidase during the fermentation process. Tea, which is the most widely consumed beverage in the world other than water, is produced from the leaves of Camellia sinensis and contains significant amounts of flavonoid compounds.
Theaflavins (TFs) are orange-red pigments with a benzotropolone structure, which are formed by the polymerization of catechins under oxidase-catalysed oxidation in the fermentation stage of black tea production. Theaflavin (in the strict sense) is a chemical compound that is the oxidation and condensation product of (−)-epicatechin and (−)-epigallocatechin. It is also known as TF1 or simply TF. "Theaflavins" collectively describes those compounds (including theaflavin) that are formed by the enzymic oxidation and condensation of tea catechins with di- and trihydroxylated B rings.
Theaflavin (TF1) and its galloyl esters represent the main red pigments in black tea; the chemical structures include TF1, TF 3-O-gallate (TF2a), TF 3′-O-gallate (TF2b), and TF 3,3′-di-O-gallate (TF3). The four primary members of the theaflavin family are thus:
The available literature regarding the pharmacological activities of TFs has revealed that TF3 has remarkable anti-inflammatory, antioxidant, anticancer, antiobesity, antiosteoporotic, and antimicrobial properties, thus posing significant effects on human health.
Typically, the concentration of theaflavins in black tea is between about 0.4% to about 1.8% by weight, with the concentration of theaflavins in green tea usually being far less. Black tea contains 30–40% polyphenols comprising mainly TFs, thearubigins (TRs), and bisflavonols. TFs are the crucial molecules that decide the quality and grade of black tea, the most consumed tea all over the world. As the smallest tea-pigments, TFs were clarified to have a positive correlation with the liquid color of black tea.
Theaflavins are commercially available in several forms. Extracting TFs from black tea in sufficient quantities for large-scale applications is a challenging and costly process, primarily due to their low content and susceptibility to oxidation into thearubigins or theabrownins. To address this, several synthesis methods have been developed, which include chemical oxidation synthesis and enzymatic synthesis. Enzymes such as polyphenol oxidase and peroxidase are present in tea plant leaves, which, for non-fermented tea, are either steamed, boiled, microwaved, or electrically heated to inactivate endogenous oxidases. Standardized theaflavin extracts are available in encapsulated dietary supplement form; some internationally renowned brands have introduced TF products, such as Life Extension's Theaflavin capsules. Research applications also use theaflavin-enriched green tea extracts, which combine both black tea theaflavins and residual green tea catechins in a single preparation.
All of the TF derivatives exhibit extensive usages in pharmaceutics, foods, and traditional medication systems. Black tea in traditional Chinese medicine — known as hóng chá (红茶) — has long been consumed both as a beverage and for its perceived health properties. In traditional Chinese tea culture, black tea (hong cha) is prized in cooler seasons; Mongolian tribes mixed it with milk and salt to counter cold winds. The specific isolation and identification of theaflavin as a molecular compound was a twentieth-century development; traditional practitioners did not distinguish theaflavin from other tea constituents.
The consumption of black tea, traditionally made by fermentation of green tea, occupies the majority market of western countries and is gaining momentum in Asia and other regions as well. The majority (75%) of the tea consumed all over the world is black tea. Black tea became a major cultural and commercial commodity in Britain from the 17th and 18th centuries onward, consumed primarily as a brewed beverage for pleasure and social ritual rather than for any identified molecular constituent.
The history of theaflavin as a defined chemical entity is relatively recent. It was not until the 1980s and 1990s, with advanced HPLC techniques, that researchers identified theaflavin-3-gallate as a major contributor to black tea's bright amber color and potential health effects. The broader research program into the health effects of black tea polyphenols — including theaflavins — grew substantially in the late 1990s and 2000s. The prominent benefits of TFs have been well documented, and excellent achievements were disclosed during the past years.
Theaflavin, the main polyphenol in black tea, has anti-inflammatory, antioxidative, anti-mutagenic, and anti-carcinogenic properties. The benzotropolone ring system of theaflavins, incorporating multiple phenolic hydroxyl groups, is structurally suited to donate hydrogen atoms to reactive oxygen species (ROS), thereby neutralizing free radicals. The pleiotropic actions of theaflavins are mediated through the modulation of various cellular signaling pathways, such as the activation of nuclear factor erythroid 2-related factor 2 (Nrf2)/Kelch-like ECH-associated protein 1 (Keap1) signaling cascade and the inhibition of mitogen-activated protein kinase (MAPK) signaling.
In a prospective laboratory study, the effects of theaflavin, a black tea-derived polyphenol, on tumor necrosis factor-alpha-mediated expression of the interleukin-8 gene in A549 cells were determined. Theaflavin inhibited tumor necrosis factor-alpha-mediated interleukin-8 gene expression, as measured by luciferase assay and Northern blot analysis, at concentrations of 10 and 30 μg/mL. Theaflavin is a potent inhibitor of interleukin-8 gene expression in vitro. The proximal mechanism of this effect involves, in part, inhibition of IκB kinase activation and activator protein-1 pathway.
LPS-induced interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1), and intercellular adhesion molecule-1 (ICAM-1) expression was inhibited by theaflavin. LPS-induced inhibitor kappa B alpha (IκBα) degradation and nuclear translocation of RelA were blocked by theaflavin. This demonstrates that NF-κB pathway suppression is a central mechanism of theaflavin's anti-inflammatory activity.
Treatment with theaflavins has been associated with increased levels of cleaved poly (ADP-ribose) polymerase (PARP) and cleaved caspases-3, -7, -8, and -9, all markers of apoptosis, and increased expression of the proapoptotic marker Bcl-2-associated X protein (Bax) and concomitant reduction in the antiapoptotic marker B-cell lymphoma 2 (Bcl-2). Additionally, theaflavin treatment reduced phosphorylated Akt, phosphorylated mechanistic target of rapamycin (mTOR), phosphatidylinositol 3-kinase (PI3K), and c-Myc levels with increased expression of the tumour suppressor p53.
While no specific analysis was performed on the mechanisms of action for lipid improvements in one major clinical trial, the authors hypothesized potential mechanisms may include reduced micellar solubility and intestinal absorption of cholesterol, increased fecal excretion of fat and cholesterol, reduced hepatic cholesterol concentration, and upregulation of the LDL receptor in liver cells. At the cellular level, theaflavin-3,3′-digallate (TF3) is a representative theaflavin of black tea and is remarkable for the anti-coronary heart disease effect. Results showed that cell size and fetal gene mRNA level were significantly reduced when pretreated with TF3 at the concentration range of 1–10 μM, and the balance of the redox system was recovered by TF3 at the concentration of 10 μM. The intracellular Ca²⁺ level decreased, Calcineurin (CaN) expression was down-regulated and the p-NFATc3 expression was up-regulated, indicating that TF3 could inhibit the activation of the CaN-NFAT signal pathway to prevent pathological cardiac hypertrophy and heart failure.
Oxygen consumption (VO₂) and energy expenditure (EE) were increased significantly in mice treated with theaflavin-rich fraction (TF) compared with the group administered vehicle alone, with no difference in locomotor activity. The mRNA levels of uncoupling protein-1 (UCP-1) and peroxisome proliferator-activated receptor gamma coactivator-1α (PGC-1α) in brown adipose tissue were increased significantly 2 hours after administration of TF. The levels of UCP-3 and PGC-1α in the gastrocnemius muscle were also increased significantly 2 and 5 hours after administration of TF. These data are from animal (mouse) studies and have not been replicated in controlled human trials.
The most clinically robust human evidence for theaflavins concerns cholesterol reduction. A double-blind, randomized, placebo-controlled, parallel-group trial set in outpatient clinics in 6 urban hospitals in China investigated the impact of a theaflavin-enriched green tea extract on lipids and lipoproteins. A total of 240 men and women aged 18 years or older, on a low-fat diet with mild to moderate hypercholesterolemia, were randomly assigned to receive a daily capsule containing theaflavin-enriched green tea extract (375 mg) or placebo for 12 weeks. The theaflavin-enriched green tea extract studied was found to be an effective adjunct to a low-saturated-fat diet to reduce LDL-C in hypercholesterolemic adults and was well tolerated.
While epidemiologic studies suggest that drinking multiple cups of tea per day lowers low-density lipoprotein cholesterol (LDL-C), previous trials of tea drinking and administration of green tea extract had failed to show any impact on lipids and lipoproteins in humans. An earlier trial that tested a capsule containing 150 mg of green tea polyphenol, but no theaflavins, showed no effect on the lipid profile, suggesting theaflavins may play a specific role in any observed lipid-lowering benefit of this preparation. This remains one of the few, and most widely cited, randomized controlled trials in humans specifically using a theaflavin-enriched extract. Overall, the human clinical evidence for cardiovascular benefits is limited to this single major RCT and requires replication.
Epidemiological and clinical studies have confirmed that black tea is a rich source of health-promoting ingredients, such as catechins and theaflavins (TFs). The antioxidant properties of theaflavins are well-characterized in vitro and in animal models. However, much of this evidence is preclinical. TFs demonstrated considerable physiological benefits in research, such as antioxidant, antiviral, antibacterial, and cancer-related properties. Nonetheless, research concerning the physiological impacts of TFs has predominantly been centered on cellular and animal studies, with a notable lack of clinical trials or research involving human subjects.
The anti-inflammatory evidence for theaflavins is primarily in vitro and animal-based. The effects of theaflavin on the expression of proinflammatory mediators, LPS-induced nuclear factor-kappa B (NF-κB), and mitogen-activated protein kinase (MAPK) signaling pathways were examined by RT-PCR, Western blotting, and immunofluorescence in bone marrow-derived macrophages isolated from ICR mice. LPS-induced IL-6, MCP-1, and ICAM-1 expression was inhibited by theaflavin. LPS-induced IκBα degradation and nuclear translocation of RelA were also blocked by theaflavin. No large, well-powered randomized controlled trials in humans specifically examining theaflavins for inflammatory endpoints have been identified. The anti-inflammatory evidence must currently be characterized as preliminary and largely preclinical.
A review summarized the current in vitro and in vivo evidence available investigating the anti-cancer effects of theaflavins across various cancer cell lines and animal models. Mechanistic studies in cell culture models have demonstrated theaflavin-associated induction of apoptosis through multiple pathways, including caspase activation, suppression of the PI3K/Akt/mTOR axis, and p53 upregulation. Liver cancer cell lines have also been studied: one study evaluated the protective effects and underlying mechanisms of high-purity TF3 (2.5/5/10 mg/kg, 12-week oral gavage) against alcoholic liver injury in C57BL/6J mice. TF3 administration significantly reduced serum lipids, attenuated hepatic steatosis, and suppressed oxidative stress and pro-inflammatory cytokine production in alcohol-fed mice.
Evidence strength: All anticancer evidence identified is in vitro or in animal models. No clinical trials in human cancer patients using isolated theaflavins as an intervention have been identified in the peer-reviewed literature. This area must be characterized as early-stage and preclinical only.
Theaflavin-3′-gallate (T3G) is a monomer of theaflavins found in black tea and is considered an important bioactive component. T3G and theaflavin (TF1) can effectively inhibit the replication of influenza viruses such as H1N1-UI182, H1N1-PR8, H3N2, and H5N1, with T3G demonstrating the most significant antiviral activity in vivo. Intraperitoneal injection of 40 mg/kg/day T3G effectively alleviated viral pneumonia, maintained body weight, and increased the survival rate of mice infected with a lethal dose of H1N1-UI182 to 55.56%.
Three different theaflavins — theaflavin (TF1), theaflavin-3′-monogallate (TF2), and theaflavin-3,3′-digallate (TF3), which are major polyphenols from black tea — were tested against hepatitis C virus (HCV) in cell culture. The results showed that all theaflavins inhibit HCV infection in a dose-dependent manner in an early step of infection. Results obtained with HCV pseudotyped virions confirmed their activity on HCV entry and demonstrated their pan-genotypic action. Investigation on the mechanism of action of black tea theaflavins showed that they act directly on the virus particle and are able to inhibit cell-to-cell spread. Combination study with inhibitors most widely used in anti-HCV treatment regimens demonstrated that TF3 exerts an additive effect.
Theaflavins and EGCG have been described to inactivate the same viruses, HSV-1, HIV-1, and influenza virus. Natural components like tea theaflavin-gallates have demonstrated supportive roles in antiviral treatments, capable of not only enhancing immune responses but also potentially inhibiting viral replication through multiple pathways, thereby alleviating lung damage.
Evidence strength: Antiviral evidence is predominantly in vitro and in animal models. No clinical trials in humans evaluating theaflavins against specific viral infections have been identified. This evidence is preliminary.
A study in mice evaluated the influence of a single oral administration of theaflavins on energy metabolism by monitoring the initial metabolic changes in skeletal muscle and brown adipose tissue (BAT). A single dose of theaflavin-rich fraction enhanced energy expenditure and was associated with upregulation of thermogenic gene expression in animal models. Theaflavin might also normalize blood sugar levels. These metabolic effects have been characterized in preclinical settings but human clinical evidence remains very limited.
Accumulating evidence suggests that theaflavins exert a wide range of biological activities, including neuroprotective, cardioprotective, nephroprotective and anti-inflammatory, antimicrobial effects. Neuroprotective effects, including attenuation of oxidative damage in neuronal models, have been reported in animal and cell-based studies. In humans, tea and coffee contain polyphenolic compounds that have antioxidant and neuroprotective properties. However, controlled clinical trials specifically isolating theaflavin as the neuroprotective agent in human subjects have not been identified in the peer-reviewed literature. This remains a preclinical area of interest.
As the primary bioactive component in fermented tea, theaflavin-3,3′-digallate (TF3) possesses potent antioxidative and anti-inflammatory capacities, though its protective mechanisms against alcoholic liver injury via the gut-liver axis require systematic elucidation. Animal studies have shown hepatoprotective effects, but controlled human trials in liver disease are lacking. While liver-protective properties of theaflavins have been documented in preclinical settings, their capacity to mitigate iron overload-induced liver damage by suppressing ferroptosis remains largely uninvestigated.
Based on the published scientific literature, theaflavins are studied in relation to the following organ systems and health domains:
In the primary human RCT on cholesterol reduction, a double-blind, randomized, placebo-controlled, parallel-group trial enrolled 240 adults with mild to moderate hypercholesterolemia who received a daily capsule containing theaflavin-enriched green tea extract (375 mg) or placebo for 12 weeks. This preparation combined both black tea theaflavins and green tea catechins in a single capsule.
In a human study, theaflavins were detected at levels as low as 1 ng/mL in plasma and 2 ng/mL in urine after consumption of 700 mg theaflavins (Mulder et al., 2001). This dose of 700 mg oral theaflavin was used in pharmacokinetic research rather than as a therapeutic protocol.
In preclinical animal studies:
Exploring particular mechanisms of action, pharmacokinetic characteristics, biosafety, and optimal dosages will establish a scientific foundation for the advancement of TFs as pharmaceuticals and functional foods. As of the most recent reviews, standardized human dosing regimens for isolated theaflavins across therapeutic indications remain undefined.
A consistent finding across the literature is that theaflavins have poor oral bioavailability. TFs have low bioavailability due to their high molecular weight and large polar surface area and thus require modifications before delivery. The intestinal stability of theaflavins is poor, leading to a low absorption rate in the small intestine, with only a minimal percentage of the ingested amount being utilized by the human body, estimated at only 0.001% of the intake.
Some researchers have reported that theaflavins show poor or limited bioavailability. In mice administered decaffeinated black tea (50 mg/g) for 2 weeks, only small amounts of theaflavin-3,3′-O-digallate (TFdG) were detected in tissues (<1 nmol/g tissue). In a human study, theaflavins were detected at levels as low as 1 ng/mL in plasma and 2 ng/mL in urine after consumption of 700 mg theaflavins.
Studies have shown that the plasma half-life of theaflavins is approximately between 1 and 3 hours, similar to or slightly shorter than that of catechins. Many factors have been found to affect the final bioavailability of phenolic compounds, such as food matrix, biological transporters, molecular structures, metabolic enzymes, and intestinal microbiota. The mechanism of poor bioavailability of theaflavins in humans, especially in the intestine, the major absorption site for xenobiotics, remains unclear.
Advances in formulations such as encapsulation and nanoformulations are of great importance as they increase the efficacy of the drug molecule and lower the dosage, toxicity, and other side effects. Nanoliposome-encapsulated TF3 was developed and showed great in vitro digestion stability. A study using chitosan and casein phosphopeptides nanocomplex to encapsulate TF3 found that the complex improved the intestinal stability and permeability.
Theaflavin is likely safe in the amounts found in brewed black tea. Theaflavin is possibly safe in the amounts found in medicine when used for up to 12 weeks. The principal human RCT on theaflavin-enriched extract (375 mg daily for 12 weeks) found the preparation to be well tolerated in 240 participants with hypercholesterolemia.
There is not enough reliable information available to know if theaflavin is safe to use when pregnant or breastfeeding.
Theaflavin might decrease blood sugar. Diabetes medications are also used to lower blood sugar. Taking theaflavin along with diabetes medications might cause blood sugar to go too low. This potential interaction is based on theaflavin's proposed glycemic effects and is a theoretical concern rather than one confirmed by documented human case reports.
Tea polyphenols, including theaflavins, are known to bind non-heme iron in the gastrointestinal tract and may reduce its absorption. This is a property shared by polyphenols generally and is relevant for individuals at risk of iron deficiency who consume large quantities of black tea with meals.
Research concerning the physiological impacts of TFs has predominantly been centered on cellular and animal studies, with a notable lack of clinical trials or research involving human subjects. Exploring particular mechanisms of action, pharmacokinetic characteristics, biosafety, and optimal dosages will establish a scientific foundation for the advancement of TFs as pharmaceuticals and functional foods. The high preparation cost, poor bioavailability, and unclear action mechanism in the human body hinder clinical application.
People take theaflavin for high levels of cholesterol or other fats in the blood, heart disease, obesity, and cancer, but there is no good scientific evidence to support these uses. Theaflavin has antioxidant, antiviral, and anti-cancer effects in test tube experiments and in animals. The effects of theaflavin in humans are not well studied. The field's most significant gap remains the absence of large-scale, independently replicated randomized controlled trials across the many areas of biological activity identified in vitro and in animal models.
Health conditions that Theaflavin may help support.
Body systems that Theaflavin may help support.
Go back